Startup · $6.1m raised
Sydney, NSW
Every investor coverage indicates participated in a round Psylo raised.
| Investor | Rounds | Invested |
|---|---|---|
| CaraMed Capital | Seed | - |
| Empath Ventures | Seed | - |
| Lionheart Ventures | Seed | - |
| Main Sequence Ventures | Seed | - |
| Negev Capital | Seed | - |
| UNSW Founders | Accelerator | - |
| Airtree’s Daniel Petre | Unnamed stage | - |
| Possible Ventures | Unnamed stage | - |
Companies Psylo acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Sam Banister | Chief Scientific Officer | SmartCompany |
| Dr Samuel Banister | Chief Scientific Officer | Startup Daily (4 Jun 2024), Startup Daily (27 Oct 2022) |
| Josh Ismin | CEO · Founder | SmartCompany |
| Joshua Ismin | CEO | Startup Daily |
Stories naming Psylo. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Psylo, a Sydney maker of psychedelic therapies, has landed a US$8 million seed round led by Tenmile while moving to the US; earlier raises in 2022 and 2021 are recalled.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
UNSW Founders honoured eight winners at its inaugural awards, with Forage taking Startup of the Year; the piece also notes Psylo's $5 million seed raise and this year's 10x Demo Day cohort.
Sydney psychedelic biotech Psylo has banked a $5 million seed round led by CSIRO's Main Sequence Ventures, its second raise since emerging from Startmate, to advance a fast-acting psilocybin therapy toward clinical trials.